MOTS-C vs PT-141 (Bremelanotide)
Updated July 21, 2026 · Reviewed by the PeptidesDB Editorial team
A data-driven comparison of MOTS-C and PT-141 (Bremelanotide) (also searched as PT-141 (Bremelanotide) vs MOTS-C) — effect profiles, evidence, side effects, and which suits weight loss, muscle, or healing goals.
Verdict
MOTS-C centers on metabolic, while PT-141 (Bremelanotide) leans toward neuro. On indexed research, PT-141 (Bremelanotide) is ahead (MOTS-C: 3 studies, Human evidence; PT-141 (Bremelanotide): 4, Preclinical). Choose by goal — and read the primary studies. This is research information, not medical advice.
Key takeaways
- •MOTS-C is strongest for metabolic; PT-141 (Bremelanotide) for neuro.
- •Evidence: MOTS-C Human evidence (3 studies) vs PT-141 (Bremelanotide) Preclinical (4).
- •Both are research-use compounds — not FDA-approved.
Effect profiles, overlaid
At a glance
Mitochondrial-Derived Peptide | Metabolic Regulator
MOTS-C vs PT-141 (Bremelanotide): side-by-side
| Metric | MOTS-C | PT-141 (Bremelanotide) |
|---|---|---|
| Class | Longevity | — |
| Regulatory status | Research use only | Research use only |
| Evidence grade | Human evidence | Preclinical |
| Studies indexed | 3 | 4 |
| Research level | Well Studied | — |
| Strongest effect | Metabolic & appetite | Neuro & mood |
| Healing & recovery | 2.0▲ | 0.0 |
| Muscle & body comp | 1.0▲ | 0.0 |
| Metabolic & appetite | 4.0▲ | 0.0 |
| Neuro & mood | 1.0 | 4.0▲ |
| Sleep & circadian | 0.0 | 0.0 |
| Inflammation & immune | 3.0▲ | 0.0 |
| Skin & aesthetics | 0.0 | 0.0 |
▲ marks the higher community effect score (0–5 perceived-effect signal, not clinical efficacy).
Mechanism & pharmacokinetics
| Property | MOTS-C | PT-141 (Bremelanotide) |
|---|---|---|
| Mechanism | Mitochondrial-derived peptide; AMPK activation / metabolic regulation | — |
| Route | Subcutaneous injection (research use) | — |
Established pharmacology — curated for well-characterized compounds and AI-summarized otherwise. A blank (—) means no reliable single value is published (half-life figures for some peptides genuinely disagree across sources). Verify against primary sources such as FDA labels and ClinicalTrials.gov.
What is MOTS-C?
### Summary MOTS-C is a mitochondrial-derived peptide that has garnered attention for its potential roles in metabolic regulation and cellular stress responses. Emerging research suggests it may have implications in various health conditions, including cardiovascular diseases and placental function.
Full MOTS-C profile, mechanism & studies →What is PT-141 (Bremelanotide)?
### Summary PT-141 (Bremelanotide) is a synthetic peptide that acts as a melanocortin receptor agonist, primarily investigated for its potential to treat sexual dysfunction, particularly in women experiencing hypoactive sexual desire disorder. Its mechanism of action involves the modulation of pathways related to sexual arousal and desire.
Full PT-141 (Bremelanotide) profile, mechanism & studies →Which is better for your goal?
| Goal | Better fit | Why |
|---|---|---|
| Healing | MOTS-C | 2.0/5 effect signal |
| Muscle | MOTS-C | 1.0/5 effect signal |
| Metabolic | MOTS-C | 4.0/5 effect signal |
| Neuro | PT-141 (Bremelanotide) | 4.0/5 effect signal |
| Inflammation | MOTS-C | 3.0/5 effect signal |
Fit reflects community-perceived effect profiles — not head-to-head trials. Read each peptide's studies before deciding.
Can you stack MOTS-C and PT-141 (Bremelanotide)?
People sometimes combine peptides that target different pathways, but there is little controlled research on this specific pairing and the interactions aren't well characterized. Because neither compound is FDA-approved, we don't publish stacking or dosing protocols here. Any combination should be discussed with a qualified clinician.
MOTS-C vs PT-141 (Bremelanotide): side effects
No community-reported effects logged yet.
No community-reported effects logged yet.
Anonymous community reports (count = number of reports), not clinical incidence rates.
What the research says
MOTS-C has 3 approved studies indexed (Human evidence), and PT-141 (Bremelanotide) has 4 (Preclinical). The Librarian re-checks PubMed, Europe PMC and ClinicalTrials daily, so these counts move. Open each profile to read the summaries and sources.
Frequently asked questions
Is MOTS-C or PT-141 (Bremelanotide) better?
It depends on your goal. MOTS-C is strongest for metabolic; PT-141 (Bremelanotide) for neuro. PT-141 (Bremelanotide) has more indexed studies (4). See the goal-by-goal breakdown above.
Is MOTS-C or PT-141 (Bremelanotide) better for weight loss?
MOTS-C shows the stronger metabolic & appetite profile (4.0/5) in community effect data — though weight-loss outcomes depend on the individual and the evidence base.
Is MOTS-C or PT-141 (Bremelanotide) better for muscle?
MOTS-C leads on the muscle & body-composition axis (1.0/5).
Which has more research, MOTS-C or PT-141 (Bremelanotide)?
MOTS-C has 3 approved studies indexed (Human evidence); PT-141 (Bremelanotide) has 4 (Preclinical). Higher counts mean more to read, not proven superiority.
Can you stack MOTS-C and PT-141 (Bremelanotide)?
Some users combine peptides, but there's little controlled data on this specific pairing, and interactions aren't well characterized. We don't publish stacking protocols for compounds that aren't FDA-approved. Discuss any combination with a qualified clinician.
What are the side effects of MOTS-C vs PT-141 (Bremelanotide)?
MOTS-C: no community-reported effects logged yet. PT-141 (Bremelanotide): none logged yet. These are anonymous reports, not incidence rates — see each profile.
Is MOTS-C or PT-141 (Bremelanotide) FDA-approved?
MOTS-C is a research-use compound and is not FDA-approved. PT-141 (Bremelanotide) is not FDA-approved. Research-use status is not a legal clearance to compound or use in humans.
Is PT-141 (Bremelanotide) better than MOTS-C?
For neuro, PT-141 (Bremelanotide) has the edge; for metabolic, MOTS-C does. Neither is universally "better" — it's goal-dependent, and both should be weighed against their evidence base above.
Comparing related peptides
Regulatory & legal status
MOTS-C and PT-141 (Bremelanotide) are research-use compounds and are not FDA-approved for human use. FDA approval and compounding rules for peptides change frequently, and research-use status is not a legal clearance for human use. The FDA does not review compounded drugs for safety, effectiveness, or quality. Verify current status with primary sources before acting. Last reviewed July 21, 2026.